Treatment of aggression in conduct disorders in children and adolescents
DOI:
https://doi.org/10.12775/QS.2025.39.58998Keywords
Conduct disorders, aggression, treatment, SSRIAbstract
Introduction and purpose: Treatment of conduct disorders is complex, reflecting their combined etiology in organic developmental issues and improper environmental influences. Therefore therapy involves complex psychotherapeutic interventions, focusing not only on the individual, but also on his family system, and sometimes including drug treatment. The purpose of this work is to discuss the most effective treatment strategies for children with aggressive behavior.
Material and method: The literature was reviewed in the Pubmed database, GoogleScholar, the positions of the Polish gynecological society with the use of keywords.
State of knowledge: Interventions for children and adolescents prioritize education and psychotherapy, with limited risperidone use due to side effects. Alternatives include stimulants, alpha agonists, atomoxetine, and SSRIs. The article examines aggression in CD and ODD, comorbid disorders (ADHD, CU, DBDNS), and behavioral treatments, emphasizing differential diagnosis and management.
Summary: First-line treatment involves optimizing pharmacotherapy, such as stimulants for ADHD with aggression, with risperidone as a secondary option. Further research and individualized approaches are needed to improve therapy.
References
1. Grzegorzewska I. Zachowania agresywne dzieci i młodzieży. Ujęcie kliniczno-rozwojowe. Polskie Forum Psychol. 2015;XX(4):DOI: 10.14656/PFP20150403.
2. Pisula A, Bryńska A. Zaburzenia zachowania u dzieci i młodzieży. Pediatr Po Dyplomie. 2015;19(1):11-20.
4. Pasalich DS, Dadds MR, Hawes DJ, Brennan J. Do callous-unemotional traits moderate the relative importance of parental coercion versus warmth in child conduct problems? An observational study. J Child Psychol Psychiatry. 2011;52(12):1308-1315. doi:10.1111/j.1469-7610.2011.02435.x
5. Kroneman LM, Hipwell AE, Loeber R, Koot HM, Pardini DA. Contextual risk factors as predictors of disruptive behavior disorder trajectories in girls: the moderating effect of callous-unemotional features. J Child Psychol Psychiatry. 2011;52(2):167-175. doi:10.1111/j.1469-7610.2010.02300.x
6. Iniewicz G, Wisniewska D, Dziekan K, Czuszkiewicz A. Attachment patterns and aggressive behaviours in adolescents suffering from mixed disorders of conduct and emotions. Psychiatria Polska. 2011;45(5):703-711.
7. Magalotti SR, Neudecker M, Zaraa SG, McVoy MK. Understanding Chronic Aggression and Its Treatment in Children and Adolescents. Curr Psychiatry Rep. 2019;21(12). doi:10.1007/s11920-019-1105-1
8. Pompili E, Carlone C, Silvestrini C, Nicolò G. Focus on aggressive behaviour in mental illness. Riv Psichiatr 2017;52(5):175-179. doi 10.1708/2801.28344
9. Remberk B. Zaburzenia psychiczne u dzieci i młodzieży. PZWL; 2020. str398
10. Adesanya DO, Johnson J, Galanter CA. Assessing and treating aggression in children and adolescents. Pediatr Med. 2021:0. doi:10.21037/pm-20-109
11. Klahr AM, Burt SA. Evaluation of the known behavioral heterogeneity in conduct disorder to improve its assessment and treatment. J Child Psychol Psychiatry. 2014;55(12):1300-1310. doi:10.1111/jcpp.12268
12. Masi G, Muratori P, Manfredi A, et al. Response to treatments in youth with disruptive behavior disorders. Compr Psychiatry. 2013;54(7):1009-1015. doi:10.1016/j.comppsych.2013.04.007
13. Lahey BB. What we need to know about callous-unemotional traits: comment on Frick, Ray, Thornton, and Kahn (2014). Psychol Bull. 2014;140(1):58-63. doi:10.1037/a0033387
14. National Collaborating Centre for Mental Health (UK); Social Care Institute for Excellence (UK). Antisocial Behaviour and Conduct Disorders in Children and Young People: Recognition, Intervention and Management. Leicester (UK): British Psychological Society; 2013.
15. NICE (National Institute for Health and Clinical Excellence). Antisocial behaviour and conduct disorders in children and young people: recognition, intervention and management. 2013;CG158
16. Risperidon. Charakterystyka Produktu Leczniczego. Producent: Orion Corporation. Opublikowano: 2 marca 2024 r.
17. Arypiprazol. Charakterystyka Produktu Leczniczego. Producent: Neuraxpharm Arzneimittel GmbH . Opublikowano 10 lutego 2023 r.
18. Stoddard J, Zik J, Mazefsky CA, DeChant B, Gabriels R. The Internal Structure of the Aberrant Behavior Checklist Irritability Subscale: Implications for Studies of Irritability in Treatment-Seeking Youth With Autism Spectrum Disorders. Behav Ther. 2020;51(2):310-319. doi:10.1016/j.beth.2019.09.006
19. Aman MG, Kasper W, Manos G i in. Line-Item Analysis of the Aberrant Behavior Checklist: Results from Two Studies of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder. J Child Adolesc Psychopharmacol. 2010;20(5):415-422. doi:10.1089/cap.2009.0120
20. McClellan L, Dominick KC, Pedapati EV, Wink LK, Erickson CA. Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opin Investig Drugs. 2017;26(8):985-989. doi:10.1080/13543784.2017.1353600
21. Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42-51. doi:10.1177/070674371506000202
22. Gorman DA, Gardner DM, Murphy AL, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60(2):62-76. doi:10.1177/070674371506000204
23. Khan S, Down J, Aouira N, et al. Current pharmacotherapy options for conduct disorders in adolescents and children. Expert Opin Pharmacother. 2019;20(5):571-583. doi:10.1080/14656566.2018.1561862
24. Shaheen M. The Effect of Clozapine on Violence / Aggression in Adults With Mental Illness and Personality Disorders: A Systematic Literature Review.BJPsych Open. 2023;9(Suppl 1):S71. Published 2023 Jul 7. doi:10.1192/bjo.2023.236
25. Blader JC, Pliszka SR, Kafantaris V, et al. Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. J Am Acad Child Adolesc Psychiatry. 2021;60(2):236-251. doi:10.1016/j.jaac.2019.12.009
26. Hambly JL, Khan S, McDermott B, Bor W, Haywood A. Pharmacotherapy of conduct disorder: Challenges, options and future directions. J Psychopharmacol. 2016;30(10):967-975. doi:10.1177/0269881116658985
27. Towbin K, Vidal-Ribas P, Brotman MA, et al. A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability. J Am Acad Child Adolesc Psychiatry. 2020;59(3):350-361. doi:10.1016/j.jaac.2019.05.015
28. Romero-Martínez Á, Murciano-Martí S, Moya-Albiol L. Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review. Behav Sci (Basel). 2019;9(5):57. Published 2019 May 23. doi:10.3390/bs9050057
29. Edwards S. Serotonin System Dysfunction and Callous-Unemotional Behavior. L&D [Internet]. 2024May30 [cited 2024Sep.12];7:103-9. Available from: https://scholarworks.iu.edu/journals/index.php/lad/article/view/38288
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karol Zagórski, Mateusz Kozik, Nina Skalska-Dziobek, Weronika Małagocka, Karolina Chybowska, Maria Naruszewicz, Przemysław Cetnarowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 238
Number of citations: 0
